Leland Gershell
Stock Analyst at Oppenheimer
(4.15)
# 1,595
Out of 4,630 analysts
744
Total ratings
39.8%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Rated: Buy | $98 → $97 | $68.88 | +40.82% | 39 | Aug 7, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $326 | $295.70 | +10.25% | 4 | Aug 7, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $48 | $9.46 | +407.40% | 17 | Aug 7, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $24 → $25 | $17.80 | +40.45% | 18 | Aug 7, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $54 | $39.89 | +35.37% | 9 | Aug 7, 2026 | |
| CLYM Climb Bio | Maintained: Buy | $18 | $13.54 | +32.94% | 6 | Aug 7, 2026 | |
| URGN UroGen Pharma | Reiterated: Buy | $50 → $60 | $46.31 | +29.56% | 48 | Aug 6, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $3.85 | - | 26 | Jul 30, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,014 → $1,037 | $866.11 | +19.73% | 18 | Jul 24, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $8 | $2.10 | +280.95% | 1 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $84.15 | - | 20 | Jul 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.19 | +219.63% | 3 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $4.06 | +638.92% | 2 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.75 | - | 2 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.75 | - | 8 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $262 | $255.62 | +2.50% | 37 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.79 | +269.88% | 7 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $283 → $230 | $46.20 | +397.84% | 4 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $4.11 | +581.27% | 21 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.659 | +1,417.45% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.31 | +663.36% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.06 | - | 34 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $4.63 | +331.97% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $21 | $7.56 | +177.78% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $2.77 | +802.53% | 44 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $26.10 | - | 7 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2,000 | $31.33 | +6,283.66% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $7.99 | +125.28% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $115.48 | - | 6 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.34 | +71.31% | 3 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $19.77 | +77.04% | 28 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $32.71 | +144.57% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $490 | $216.98 | n/a | 42 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.44 | n/a | 20 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $36.14 | n/a | 10 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $106 | $77.49 | n/a | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.7311 | n/a | 19 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.25 | n/a | 17 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $1.26 | n/a | 19 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.11 | n/a | 16 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.16 | n/a | 6 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $0.1288 | n/a | 11 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $200 | $0.0001 | n/a | 11 | Mar 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $0.0002 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $0.2551 | n/a | 11 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.8327 | n/a | 16 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $1.89 | n/a | 7 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | n/a | 4 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.20 | n/a | 13 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.75 | n/a | 22 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.15 | n/a | 9 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.008 | n/a | 15 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.8701 | n/a | 3 | May 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.41 | n/a | 9 | May 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.98 | n/a | 9 | Apr 3, 2019 |
BioMarin Pharmaceutical
Aug 7, 2026
Rated: Buy
Price Target: $98 → $97
Current: $68.88
Upside: +40.82%
Ligand Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $326
Current: $295.70
Upside: +10.25%
Corbus Pharmaceuticals Holdings
Aug 7, 2026
Reiterated: Buy
Price Target: $48
Current: $9.46
Upside: +407.40%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $24 → $25
Current: $17.80
Upside: +40.45%
Immunovant
Aug 7, 2026
Reiterated: Buy
Price Target: $54
Current: $39.89
Upside: +35.37%
Climb Bio
Aug 7, 2026
Maintained: Buy
Price Target: $18
Current: $13.54
Upside: +32.94%
UroGen Pharma
Aug 6, 2026
Reiterated: Buy
Price Target: $50 → $60
Current: $46.31
Upside: +29.56%
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.85
Upside: -
argenx SE
Jul 24, 2026
Reiterated: Buy
Price Target: $1,014 → $1,037
Current: $866.11
Upside: +19.73%
Palisade Bio
Jul 23, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.10
Upside: +280.95%
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $84.15
Upside: -
Jun 30, 2026
Reiterated: Buy
Price Target: $7
Current: $2.19
Upside: +219.63%
Jun 24, 2026
Maintained: Buy
Price Target: $30
Current: $4.06
Upside: +638.92%
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $3.75
Upside: -
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $1.75
Upside: -
Jun 15, 2026
Reiterated: Buy
Price Target: $262
Current: $255.62
Upside: +2.50%
Jun 15, 2026
Reiterated: Buy
Price Target: $14
Current: $3.79
Upside: +269.88%
May 27, 2026
Reiterated: Buy
Price Target: $283 → $230
Current: $46.20
Upside: +397.84%
May 20, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $4.11
Upside: +581.27%
May 15, 2026
Reiterated: Buy
Price Target: $10
Current: $0.659
Upside: +1,417.45%
May 6, 2026
Reiterated: Buy
Price Target: $10
Current: $1.31
Upside: +663.36%
Apr 13, 2026
Rated: Hold
Price Target: n/a
Current: $23.06
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: $20
Current: $4.63
Upside: +331.97%
Feb 27, 2026
Maintained: Buy
Price Target: $35 → $21
Current: $7.56
Upside: +177.78%
Feb 12, 2026
Reiterated: Buy
Price Target: $25
Current: $2.77
Upside: +802.53%
Feb 10, 2026
Rated: Hold
Price Target: n/a
Current: $26.10
Upside: -
Nov 14, 2025
Maintained: Buy
Price Target: $2,000
Current: $31.33
Upside: +6,283.66%
Nov 7, 2025
Maintained: Buy
Price Target: $18
Current: $7.99
Upside: +125.28%
Nov 4, 2025
Downgraded: Hold
Price Target: n/a
Current: $115.48
Upside: -
Oct 14, 2025
Reiterated: Buy
Price Target: $4
Current: $2.34
Upside: +71.31%
Sep 29, 2025
Reiterated: Buy
Price Target: $35
Current: $19.77
Upside: +77.04%
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $80
Current: $32.71
Upside: +144.57%
Aug 4, 2025
Upgraded: Buy
Price Target: $490
Current: $216.98
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: $25
Current: $1.44
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $36.14
Upside: n/a
May 14, 2024
Maintained: Buy
Price Target: $106
Current: $77.49
Upside: n/a
Mar 28, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $0.7311
Upside: n/a
Dec 18, 2023
Maintained: Buy
Price Target: n/a
Current: $4.25
Upside: n/a
Nov 13, 2023
Maintained: Buy
Price Target: $11
Current: $1.26
Upside: n/a
Jul 10, 2023
Maintained: Buy
Price Target: n/a
Current: $2.11
Upside: n/a
Oct 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $5.16
Upside: n/a
May 26, 2022
Maintained: Buy
Price Target: $60
Current: $0.1288
Upside: n/a
Mar 21, 2022
Maintained: Buy
Price Target: $70 → $200
Current: $0.0001
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $0.0002
Upside: n/a
Jun 2, 2021
Rated: Buy
Price Target: $12
Current: $0.2551
Upside: n/a
May 18, 2021
Rated: Buy
Price Target: $7
Current: $0.8327
Upside: n/a
May 7, 2021
Initiated Coverage: Buy
Price Target: $42
Current: $1.89
Upside: n/a
May 6, 2021
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $14.20
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $9.75
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $1.15
Upside: n/a
Sep 11, 2020
Rated: Hold
Price Target: n/a
Current: $0.008
Upside: n/a
May 10, 2019
Reiterated: Buy
Price Target: $7
Current: $0.8701
Upside: n/a
May 9, 2019
Rated: Hold
Price Target: n/a
Current: $1.41
Upside: n/a
Apr 3, 2019
Reiterated: Buy
Price Target: $8
Current: $2.98
Upside: n/a